Prioritisation of COVID-19 boosters in the omicron era

Affiliations

¹ Kaiser Permanente Center for Health Research, Portland, OR 97227, USA. Electronic address: stephanie.a.irving@kpchr.org.
² Center for Clinical Epidemiology and Population Health, Marshfield Clinic, Marshfield WI, USA.

Comment

Stephanie A Irving et al. Lancet. 2022.

. 2022 Oct 15;400(10360):1282-1283.

doi: 10.1016/S0140-6736(22)01971-7.

¹ Kaiser Permanente Center for Health Research, Portland, OR 97227, USA. Electronic address: stephanie.a.irving@kpchr.org.
² Center for Clinical Epidemiology and Population Health, Marshfield Clinic, Marshfield WI, USA.

No abstract available

Figures

Severe COVID-19 outcomes after full vaccination of primary schedule and initial boosters: pooled analysis of national prospective cohort studies of 30 million individuals in England, Northern Ireland, Scotland, and Wales.
Agrawal U, Bedston S, McCowan C, Oke J, Patterson L, Robertson C, Akbari A, Azcoaga-Lorenzo A, Bradley DT, Fagbamigbe AF, Grange Z, Hall ECR, Joy M, Katikireddi SV, Kerr S, Ritchie L, Murphy S, Owen RK, Rudan I, Shah SA, Simpson CR, Torabi F, Tsang RSM, de Lusignan S, Lyons RA, O'Reilly D, Sheikh A. Agrawal U, et al. Lancet. 2022 Oct 15;400(10360):1305-1320. doi: 10.1016/S0140-6736(22)01656-7. Lancet. 2022. PMID: 36244382 Free PMC article.

1. Andrews N, Stowe J, Kirsebom F, et al. COVID-19 vaccine effectiveness against the omicron (B.1.1.529) variant. N Engl J Med. 2022;386:1532–1546. - PMC - PubMed
1. Sheikh A, Kerr S, Woolhouse M, et al. Severity of omicron variant of concern and effectiveness of vaccine boosters against symptomatic disease in Scotland (EAVE II): a national cohort study with nested test-negative design. Lancet Infect Dis. 2022;22:959–966. - PMC - PubMed
1. Link-Gelles R, Levy ME, Gaglani M, et al. Effectiveness of 2, 3, and 4 COVID-19 mRNA vaccine doses among immunocompetent adults during periods when SARS-CoV-2 omicron BA.1 and BA.2/BA.2·12·1 sublineages predominated—VISION Network, 10 states, December 2021–June 2022. MMWR Morb Mortal Wkly Rep. 2022;71:931–939. - PMC - PubMed
1. Kirsebom FCM, Andrews N, Stowe J, et al. COVID-19 vaccine effectiveness against the omicron (BA.2) variant in England. Lancet Infect Dis. 2022;22:931–933. - PMC - PubMed
1. Clift AK, Coupland CAC, Keogh RH, et al. Living risk prediction algorithm (QCOVID) for risk of hospital admission and mortality from coronavirus 19 in adults: national derivation and validation cohort study. BMJ. 2020;371 - PMC - PubMed